Navigation Links
NYU Cancer Institute experts present at American Society of Clinical Oncology annual meeting
Date:5/21/2010

Experts from The Cancer Institute at NYU Langone Medical Center will present new research findings at the 46th Annual Meeting of The American Society of Clinical Oncology (ASCO) in Chicago, Illinois. The conference will run from June 4-8, 2010 and scientists from the NYU Cancer Institute will be available to discuss various topics including improved ways to diagnose melanoma in lymphatic vessels, genetic differences in melanoma subtypes and post-transplant lymphoproliferative disorders that are a potential serious complication after organ or bone marrow transplant.

Laura Hogan, MD, pediatric hematology and oncology fellow at the NYU Cancer Institute will receive The Brigid Leventhal Merit Award at ASCO for her outstanding work in pediatric oncology research. Dr. Hogan is the fellow with the highest ranking pediatric abstract at the 2010 Annual Meeting entitled, "High Throughput Transcriptome Sequencing of Pediatric Relapsed Acute Lymphoblastic Leukemia (ALL)."


Abstract # 9521: Sunday, June 6th at 2:00 PM in Chicago, IL
High Throughput Transcriptome Sequencing of Pediatric Relapsed Acute Lymphoblastic Leukemia (ALL)
Presenter: William Carroll, MD, director, NYU Cancer Institute and Julie and Edward J. Minskoff Professor of Pediatrics, Oncology
Lead Author: Laura Hogan, MD, Pediatric Hematology/Oncology Fellow, NYU Cancer Institute

Acute lymphoblastic leukemia is the most common childhood cancer and relapse occurs in approximately 20% of patients. For relapsed pediatric acute lymphoblastic leukemia (ALL) cases, researchers have investigated RNA transcriptome sequencing to identify gene mutations. Some of these mutations are located in novel genes that haven't been associated with cancer previously. While some of these mutations are shared among patients, others are unique to an individual. In this study, researchers indicate that a diversity of pathways may be responsible for relapse in pediatric ALL. This
'/>"/>

Contact: Lauren Woods
lauren.woods@nyumc.org
212-404-3753
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Page: 1 2 3 4 5 6

Related biology news :

1. Gene fusions may be the smoking gun in prostate cancer development, U-M study finds
2. Study raises new concerns about radiation and breast cancer
3. Slight changes in 2 key genes appear to launch breast cancer development
4. TGen researcher awarded American Cancer Society fellowship
5. Einstein researcher awarded prestigious cancer research grant
6. Cancer: Trapping the escape artist
7. U-M study achieves reduced side effects in head and neck cancer treatment
8. Milk and risk of renal cell cancer: Genetic research sheds new light
9. Multistage nanovector system provides sustained delivery of siRNA cancer therapeutic in mice
10. Key mechanism identified in metastatic breast cancer
11. Flaxseed-fed chickens shed light on ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... and engineers must join together in a major new ... a crisis in providing Earth,s people with clean water ... focus of a comment article in the current edition ... newsmagazine of the American Chemical Society (ACS), the world,s ... L. Sedlak, Ph.D., and Jerald L. Schnoor, Ph.D., explain ...
(Date:5/22/2013)... drastically reduces the time and effort needed to ... biotechnology, scientists are reporting. Published in the journal ... the way for more rapid development of designer ... activities. , Keith Shearwin and colleagues explain that ... material DNA into a bacterium,s genome is critical ...
(Date:5/22/2013)... can endanger the whole organism, as they may lead ... in Munich now report how byproducts of respiration cause ... DNA in our cells controls the form and function ... for this are encoded in the linear sequence of ... (A), cytosine (C), guanine (G) and thymine (T). Random ...
Breaking Biology News(10 mins):DNA damage: The dark side of respiration 2
... much difference can a tenth of a nanometer make? When ... in resolution of that miniscule amount can mean the difference ... Case in point: New, improved-resolution views of a zinc ... National Laboratory provide not just a structure but also a ...
... cells to turn into disease-fighting ,Natural Killer, (NK) immune cells ... Nature Immunology today. The discovery could one day ... cells, creating new ways to treat cancer. The ... E4bp4, in a mouse model, creating the world,s first animal ...
... the flowers of Edinburgh in full bloom in the depths of ... impact of global warming on spring flowering, published today in the ... back to the late nineteenth century, has been used to demonstrate ... warming will have on plant life by the year 2080. ...
Cached Biology News:High-res view of zinc transport protein 2High-res view of zinc transport protein 3Master gene that switches on disease-fighting cells identified by scientists 2Master gene that switches on disease-fighting cells identified by scientists 3Early spring time for Edinburgh? Study predicts effect of global warming on spring flowers 2
(Date:5/23/2013)... 2013 The maker community is a ... inventions. They focus on learning practical skills while applying ... toward bringing their ideas to life via crowdfunding. A ... on making projects using biology. Glowing Plant has worked ... make them glow with bioluminescence genes, and has now ...
(Date:5/23/2013)... MENLO PARK, Calif. , May 23, 2013 /PRNewswire/ ... an oral treatment for pain has reached an important ... clinical trial of VBY-036 - a selective cathepsin S ... of VBY-036 is a double-blind, randomized, placebo-controlled study designed ... escalating doses of VBY-036 in healthy adults. ...
(Date:5/23/2013)... 2013 Northwest Biotherapeutics (NASDAQ: NWBO ... personalized immune therapies for solid tumor cancers, announced ... year,s American Society Of Clinical Oncology (ASCO) meeting in ... role in immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ... the pre-eminent conference focused on clinical treatment of cancer, ...
(Date:5/23/2013)... 2013 During the conduct of ... adhere to principles of good clinical practice (GCP) ... Dr. Jeremy Lim, Fellow, Clinical Development at Novartis ... ,     Understand the International Conference on Harmonization (ICH) ... regulations for the conduction of clinical trials , ...
Breaking Biology Technology:Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Adhering to Good Clinical Practice, New Webinar Hosted by Xtalks 2
... 13 /PRNewswire/-- DATATRAK International, Inc. (OTCQX: DATA), a technology and ... clinical trials industry, announced today that Zacks Investment Research ... 13, 2010. Zacks is a leading provider of independent ... report can be obtained by contacting Mr. Ken Nagy, ...
... 13 Matthew F. Heil, Ph.D., senior vice president of ... ), a drug research and development company focused on the ... Forum 2010 in Laval, Canada, at the invitation of the ... the Laval Technopole International Business Centre and The Biotech City ...
... BALTIMORE, Sept. 13 Champions Biotechnology, Inc. (OTC Bulletin Board: ... of advanced preclinical platforms and tumor specific data to enhance ... for the fiscal 2011 first quarter ended July 31, 2010. ... in the Company,s Form 10-Q at www.championsbiotechnology.com . ...
Cached Biology Technology:DATATRAK International, Inc. Announces Initial Equity Research Coverage by Zacks Investment Research 2DATATRAK International, Inc. Announces Initial Equity Research Coverage by Zacks Investment Research 3Curemark Attends North American Bio Forum at Canadian Government Invitation 2Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results 4
Mouse monoclonal [2D7/1] to E.coli LPS ( Abpromise for all tested applications). Antigen: Tissue / cell preparation: Escherichia coli J5 cells....
fli-1...
Purified Mouse anti-Hu p120 Catenin (pT916) Storage Temperature: Refrigerate(2 to 8C)...
Request Info...
Biology Products: